Results 191 to 200 of about 74,157 (302)

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes   +7 more
wiley   +1 more source

Comparative ocular safety of dupilumab and oral Janus kinase inhibitors in atopic dermatitis: A real-world propensity-matched analysis. [PDF]

open access: yesJAAD Int
Adler R   +8 more
europepmc   +1 more source

JI‐CJ002 and Dabrafenib Combination Enhances Antitumor Activity in Melanoma Associated With the Downregulation of B7‐H3

open access: yesCancer Science, EarlyView.
Schematic pathway diagram illustrating the effects of JI‐CJ002 and dabrafenib on melanoma progression. The combination of JI‐CJ002 and dabrafenib is associated with reduced B7‐H3 expression and modulation of signaling pathways implicated in melanoma progression, including JAK2/STAT3, PI3K/AKT/mTOR, and Rb/E2F1.
Sang‐Eun Lee   +4 more
wiley   +1 more source

Multifunctional Role of Mitochondrial Fatty Acid Oxidation in Cancer Immunotherapy and Aging

open access: yesCancer Science, EarlyView.
Recent studies have highlighted the complex interplay between tumor immunity, aging, and inflammation. Mitochondrial FAO is a major hub of this physiological interplay. ABSTRACT Recent studies have demonstrated the intricate relationship between tumor immunity, aging, and inflammation.
Koji Kitaoka   +4 more
wiley   +1 more source

Janus kinase inhibitors in pulmonary and extra-pulmonary sarcoidosis: A case series and a systematic review of the literature. [PDF]

open access: yesSarcoidosis Vasc Diffuse Lung Dis
Quaggetto M   +7 more
europepmc   +1 more source

Effect of Delgocitinib Cream on Health‐Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema

open access: yesContact Dermatitis, EarlyView.
Patient‐reported outcomes are an important complement to physician‐assessed clinical outcome measures in Chronic Hand Eczema. In a pooled analysis of two randomised, controlled trials, twice‐daily treatment with delgocitinib cream 20 mg/g significantly improved the health‐related quality of life of patients with moderate to severe Chronic Hand Eczema ...
Andrea Bauer   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy